NVCT (Nuvectis Pharma) Other Financing: $-0.81 Mil (TTM As of Mar. 2026)


NVCT Nuvectis Pharma Inc NVCT
22 GF Score
Price $28.52
! 2 Warning Signs
View Full Analysis

What is Nuvectis Pharma Other Financing?

Nuvectis Pharma NVCT +4.93% 22 Other Financing is $-0.81 Mil as of Mar. 2026. GuruFocus rates NVCT with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Nuvectis Pharma's Other Financing for the three months ended in Mar. 2026 was $0.00 Mil.

Nuvectis Pharma's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.81 Mil.

Nuvectis Pharma Other Financing Historical Data

* Premium members only.

The historical data trend for Nuvectis Pharma's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuvectis Pharma Other Financing Chart

Nuvectis Pharma Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial 0.00 -4.07 9.80 -0.38 -2.10

Nuvectis Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.29 -0.32 -0.41 -0.08 0.00
NVCT
22GF Score
Nuvectis Pharma Inc NVCT
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nuvectis Pharma Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-0.81 Mil mean?
Nuvectis Pharma (NVCT) has a Other Financing of $-0.81 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Nuvectis Pharma and its competitors.
Is Nuvectis Pharma's Other Financing too high?
Nuvectis Pharma's current Other Financing is $-0.81 Mil. Overall, Nuvectis Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Nuvectis Pharma's Other Financing compare to AURA and OCS?
Nuvectis Pharma's Other Financing of $-0.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Nuvectis Pharma and its competitors. Nuvectis Pharma's current Other Financing is $-0.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvectis Pharma stock overvalued right now?
Nuvectis Pharma (NVCT) has a current Other Financing of $-0.81 Mil. The current Other Financing is $-0.81 Mil. Nuvectis Pharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Nuvectis Pharma (NVCT), the current Other Financing is $-0.81 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nuvectis Pharma Business Description

Address 1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, NJ, USA, 07024
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
22GF Score

Get the complete analysis for NVCT

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.52
Price